In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now. On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation ...

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Wells Fargo on May 30, 2025. The analyst firm set a price target for $59.00 expecting TECH to rise to within 12 months (a possible ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...

(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...

Bio-Techne Corporation TECH is set to release fourth-quarter fiscal 2025 results on Aug. 6, before the opening bell. The life science and diagnostic product maker posted adjusted earnings per share ...

MINNEAPOLIS - Bio-Techne Corporation (NASDAQ:TECH) announced today the launch of SPYRE Focus Panels and SPYRE Amplification Kits as additions to its COMET spatial biology solution portfolio, according ...

MINNEAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m.